ArticleSeizure2026
Characteristics associated with first anti-seizure medication prescribed in a cohort of adults with newly diagnosed epilepsy.
Article in Seizure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAnti-seizure medication (ASM) is the primary treatment modality in epilepsy. There exist evidence-based recommendations published by the American Academy of Neurology and American Epilepsy Society for ASM selection in epilepsy, but these medication recommendations are inconsistently followed. We sought to examine predictors of recommended first ASM in newly diagnosed adults with epilepsy.
methodsWe conducted a retrospective cohort study of adults (≥18 years) newly diagnosed with epilepsy in New York, identified using validated ICD-CM codes, for the period 2011 to 2019. The primary outcome of interest was use of an AES/AAN guideline-informed ASM, and exposures of interest included patient characteristics (e.g. age), provider characteristics (e.g. specialty) and structural characteristics (e.g., practice setting). Multivariable Poisson regression for risk ratios modeled the probability of being prescribed a neutral/recommended or non-recommended ASM, adjusting for covariates.
results2340 adults with newly diagnosed epilepsy were prescribed an ASM within 1-year. The most frequently prescribed ASM was levetiracetam (45.5%), which aligns with recommendations. However, 39% were prescribed a non-recommended medication. The prescription of a recommended ASM was associated with older age at diagnosis (relative risk (RR) 1.01; 95% confidence interval (CI) 1.00-1.01), Black race (RR 1.12; 95% CI 1.03-1.23), being in a relationship (vs. divorced/separated/single or widowed) (RR 1.13; 95% CI 1.06-1.22) and a history of stroke (RR 1.19; 95% CI 1.05-1.34). Prescriptions from physician trainees (vs. non-trainees) were more likely to align with recommended ASMs (RR 1.15; 95% CI 1.06-1.25), with no differences by physician specialty. Inpatient setting was associated with fewer recommended ASM prescriptions (vs. outpatient setting) (RR 0.82; 95% CI 0.75-0.89). There was no difference between emergency department and outpatient prescriptions.
conclusionsUnderstanding where/why less favorable ASM prescription may occur is important to target potential prescribing interventions. In this study, recommended ASM prescriptions were associated with patient, prescriber and setting characteristics. Notably, trainees prescribed recommended/neutral ASM more often, which underscores the importance of prescriber education in improving prescribing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.